MGP Panel is a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients.

Journal article

Sudha P. et al, (2022), Clin Cancer Res

A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.

Journal article

Ravichandran S. et al, (2022), Br J Haematol

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

Journal article

Dimopoulos MA. et al, (2022), Blood Cancer J, 12

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response.

Journal article

Ramasamy K. et al, (2022), Br J Haematol

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.

Journal article

Djebbari F. et al, (2022), PLoS One, 17

Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort.

Journal article

Maouche N. et al, (2021), J Oncol Pharm Pract

Multiple myeloma screening within a fracture liaison service (FLS).

Journal article

Agarwal G. et al, (2021), Osteoporos Int

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response

Ramasamy K. et al, (2021)

Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care.

Journal article

Seesaghur A. et al, (2021), BMJ Open, 11

CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

Conference paper

Popat R. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S2 - S3

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.

Journal article

Ramasamy K. et al, (2021), Blood Cancer J, 11

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options.

Journal article

Ramasamy K. et al, (2021), Blood Rev, 49

Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins.

Journal article

Campbell L. et al, (2021), Clin Biochem, 95, 81 - 83

COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.

Journal article

Ramasamy K. et al, (2021), Br J Haematol

The management of Castleman disease.

Journal article

Lomas OC. et al, (2021), Br J Haematol

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Journal article

Anderson KC. et al, (2021), Clin Cancer Res

Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report.

Journal article

Rana R. et al, (2021), BMJ Open Qual, 10

Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.

Journal article

Maouche N. et al, (2021), Leuk Lymphoma, 62, 1396 - 1404

Management of patients with difficult-to-treat multiple myeloma.

Journal article

Richter J. et al, (2021), Future Oncol, 17, 2089 - 2105

COVID symptoms, testing, shielding impact on patient reported outcomes and early vaccine responses in individuals with multiple myeloma

Ramasamy K. et al, (2021)